Drug · CHEMBL408403
ANGIOTENSIN II
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ANGIOTENSIN II. Drugs and targets, record CHEMBL408403. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL408403
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 5-l-isoleucineangiotensin ii, Angiotensin ii (human type), Angiotensin ii human, Angiotensina ii, Angiotensine ii, Asp-arg-val-tyr-ile-his-pro-phe, Delivert, LJPC-501
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 17 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | Type-1 angiotensin II receptor agonist | AGONIST | https://conductscience.org/library/genes/185 |
Source ChEMBL
Diseases17
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 17Source Open Targets
See all 17 diseasesTrials38
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02338843 | A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension | Phase 3 | 344 | 2018-01-17 | angiotensin II | Its name | ClinicalTrials.gov |
| NCT03733145 | Angiotensin II in General Anesthesia | Phase 4 | 32 | 2025-08-24 | angiotensin II | Its name | ClinicalTrials.gov |
| NCT04558359 | Renin and Renal Biomarker Response to Angiotensin II | Phase 4 | 30 | 2024-09-04 | angiotensin II | Its name | ClinicalTrials.gov |
| NCT00962949 | The Renin-Aldosterone Axis in Postural Tachycardia Syndrome | Phase 1 | 28 | 2018-08-17 | angiotensin II | Its name | ClinicalTrials.gov |
| NCT01393782 | Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study | Phase 1 | 20 | 2024-04-12 | angiotensin II | Its name | ClinicalTrials.gov |
| NCT04529005 | Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients | Phase 4 | 20 | 2022-12-21 | angiotensin II | Its name | ClinicalTrials.gov |
| NCT06615102 | Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II | Phase 3 | 1,022 | angiotensin II | Its name | ClinicalTrials.gov | |
| NCT02966665 | : Vascular Function in Health and Disease | Phase 1 | 420 | angiotensin II | Its name | ClinicalTrials.gov | |
| NCT06351150 | Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock | Phase 3 | 214 | angiotensin II | Its name | ClinicalTrials.gov | |
| NCT01426529 | Caveolin-1 and Vascular Dysfunction | Phase 1 | 120 | angiotensin II | Its name | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
LJPC-501 (Angiotensin II) vs Placebo (0.9% Sodium Chloride Solution): An Increased MAP, Defined as Achievement of a Day 1 MAP at 3 Hours Following the Initiation of Study Drug, of ≥ 75 mmHg OR a 10 mmHg Increase in Baseline MAP | 114 of 163 | 37 of 158 | 321 | NCT02338843 | Trial comparisons |
| LJPC-501 (Angiotensin II) vs Placebo (0.9% Sodium Chloride Solution): deaths from any cause | 75 of 163 | 85 of 158 | 321 | NCT02338843 | Trial comparisons |
| LJPC-501 (Angiotensin II) vs Placebo (0.9% Sodium Chloride Solution): serious adverse events | 99 of 163 | 106 of 158 | 321 | NCT02338843 | Trial comparisons |
| Postural Tachycardia Syndrome vs Control: deaths from any cause | 0 of 15 | 0 of 13 | 28 | NCT00962949 | Trial comparisons |
| Postural Tachycardia Syndrome vs Control: serious adverse events | 0 of 15 | 0 of 13 | 28 | NCT00962949 | Trial comparisons |
| Angiotensin II Cohort vs Standard of Care Cohort: Number of Participants With In-hospital Mortality | 9 of 18 | 9 of 10 | 28 | NCT04558359 | Trial comparisons |
| Angiotensin II Cohort vs Standard of Care Cohort: deaths from any cause | 9 of 18 | 9 of 10 | 28 | NCT04558359 | Trial comparisons |
| Angiotensin II Cohort vs Standard of Care Cohort: Number of Participants Experiencing Prespecified Safety Outcomes | 0 of 18 | 0 of 10 | 28 | NCT04558359 | Trial comparisons |
| Angiotensin II Cohort vs Standard of Care Cohort: serious adverse events | 0 of 18 | 0 of 10 | 28 | NCT04558359 | Trial comparisons |
| Angiotensin vs Control: Mortality | 5 of 10 | 6 of 10 | 20 | NCT01393782 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials20
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 24466071 | RESULT | 1 | PubMed |
| 39972379 | DERIVED | 1 | PubMed |
| 38870103 | DERIVED | 1 | PubMed |
| 38637829 | DERIVED | 1 | PubMed |
| 38103056 | DERIVED | 1 | PubMed |
| 37984940 | DERIVED | 1 | PubMed |
| 37147690 | DERIVED | 1 | PubMed |
| 32609011 | DERIVED | 1 | PubMed |
| 32028998 | DERIVED | 1 | PubMed |
| 31298286 | DERIVED | 1 | PubMed |
1 to 10 of 20
See all 20 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL408403
GET https://conductscience.org/api/drugs/v1/CHEMBL408403/trials?page=2